The Longevity Series — Guides
AMPK, Senolytics & Telomeres: The Cellular Longevity Pathways, Explained
Last updated 19 August 2026
Three different biological targets, three different supplement categories — and, for senolytics especially, a real gap between the mouse data and what's actually been shown in people.
AMPK: the cell's energy sensor
AMPK (AMP-activated protein kinase) is an enzyme that acts as the cell's energy sensor, activating when energy is low and helping regulate metabolism. Compounds studied for AMPK activation include berberine and alpha-lipoic acid — both used in formulas positioned around metabolic and mitochondrial support. Berberine has real human trial data behind AMPK-adjacent metabolic outcomes; see our Berberine vs Dihydroberberine guide for the actual meta-analysis figures.
Senolytics: clearing senescent cells — the honest version
Senescent cells are cells that have stopped dividing but don't die off — they accumulate with age. "Senolytic" compounds are researched for their potential role in clearing these cells. Here's the part that matters: the combination that has been most clearly shown to reduce senescent cell markers in humans is dasatinib plus quercetin — dasatinib being a prescription cancer drug, not a supplement ingredient.1 A small open-label pilot in 14 patients with pulmonary fibrosis using this combination showed improved physical function measures within days of dosing, but that's a specific patient population on a prescription drug, not a healthy adult taking a flavonoid capsule.2
Fisetin, the flavonoid most commonly used in supplement-only senolytic formulas, showed strong results as a senolytic in mice and in human tissue samples in lab studies.3 But when tested in the National Institute on Aging's rigorous Interventions Testing Program — a gold-standard, multi-site mouse lifespan study — fisetin did not reproduce the lifespan-extension benefit seen in earlier, smaller studies. Mayo Clinic has multiple human trials of fisetin underway (including AFFIRM and a COVID-19 pilot), but as of the most recent public information, these trials had not yet published results confirming a senolytic effect in people.4 A related Phase 2 trial of dasatinib+quercetin in postmenopausal women with osteoporosis found no significant difference across the whole treatment group, though a subset of responders did show improved bone density.5
The honest summary: senolytics are a genuinely exciting area of ageing research, but the human evidence for supplement-only formulas (fisetin, quercetin, apigenin and similar, without a prescription drug) is still thin. Treat these formulas as inspired by an active research field, not as a proven intervention.
Telomeres: the caps on your DNA
Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division. Nutrients like astragalus extract (astragaloside IV), resveratrol and astaxanthin are studied for their antioxidant role in supporting normal cellular ageing processes. This remains an earlier-stage research area than AMPK or even senolytics, with less direct human outcome data.
How the three relate
| Pathway | What it targets | Common actives |
|---|---|---|
| AMPK | Cellular energy metabolism | Berberine, ALA, CoQ10, B12 |
| Senolytic | Senescent cell clearance (research area) | Fisetin, Quercetin, Apigenin, Curcumin |
| Telomere | Antioxidant protection of DNA | Astragalus, Resveratrol, PQQ, Astaxanthin |
Do you need all three?
These are three distinct formulas addressing different angles of cellular ageing, not a single stack. Most people start with one based on their primary interest, then layer in a second after establishing a routine. See How to Build a Longevity Supplement Stack for a broader view including NMN and resveratrol.
Shop the Longevity Series →Frequently asked questions
Are these clinically proven to extend lifespan?
No human supplement has been proven to extend lifespan. These formulas are inspired by ongoing academic research into cellular ageing pathways and are sold as food supplements, not medicines.
Is fisetin proven to work as a senolytic in humans?
Not yet conclusively. It performs well in mice and human cell/tissue studies, but human trials at Mayo Clinic are still ongoing and have not published results confirming the effect in people. The clearest human evidence for senolytic activity uses a prescription drug (dasatinib) alongside quercetin, not fisetin alone.
Can I take AMPK, senolytic and telomere formulas together?
They target different pathways and can be taken alongside each other as part of a broader routine — follow the label dose on each and consult your doctor if you take any medication.
Who should not take these?
Not suitable for under-18s or for women who are pregnant or breastfeeding. If you take medication or have a medical condition, speak to your doctor before use.
Keep reading
How to Build a Longevity Supplement Stack · NMN Supplements UK: The Complete Guide · All guides
- Only the dasatinib + quercetin combination has been clearly shown to clear senescent cells in humans to date; dasatinib is a prescription drug, not a supplement ingredient.
- Pilot open-label study, 14 patients with idiopathic pulmonary fibrosis, 9 pulse-doses of dasatinib+quercetin over 3 weeks — improved physical performance measures within days of the final dose.
- Fisetin senolytic activity demonstrated in murine and human tissue studies (Mayo Clinic); underperformed in the NIA Interventions Testing Program's mouse lifespan study relative to earlier findings.
- Mayo Clinic fisetin human trials (AFFIRM, NCT03430037; COVID-FIS pilot) enrolled but had not published confirmatory senolytic results as of the most recent public information.
- Phase 2 RCT, 60 postmenopausal women, dasatinib+quercetin for osteoporosis — no significant whole-group effect on bone density; a responder subgroup showed improvement.
This guide is for general information only and does not constitute medical advice. These products are food supplements, not medicines — they are not intended to diagnose, treat, cure or prevent any disease.